A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
← catalyst calendarSponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
805actual
Sites
9
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-15 | actual | When the study began enrolling |
| Primary completion | 2025-07-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-30 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
Intervention
- Other: No drug
Primary outcome
what the primary-completion date above is the date OFPercentage of patients receiving first-line, second-line, and third-line anti-tumor regimens
measured 72 months
Publications
- PMID 42217113 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed